EUCTR2021-002609-93-PL进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 213
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Participants who have a diagnosis of CSU refractory to H1-AH at the time of randomization
- •- Diagnosis of CSU =3 months prior to screening visit (Visit 1).
- •- The presence of itch and hives for =6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period.
- •- Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication.
- •- Participants who are omalizumab naïve OR omalizumab-incomplete
- •responders.
- •- Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
- •- During the 7 days before randomization: UAS7 =16 and ISS7 =8
- •- Body mass index (BMI) >17.5 and <40 kg/m2.
- •- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 73
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •- Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria)
- •- Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
- •- Participants with active atopic dermatitis (AD).
- •- Severe concomitant illness(es) that, in the Investigator’s judgment, would adversely affect the patient’s participation in the study.
- •- Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
- •- History of serious infections requiring intravenous (IV) therapy with
- •the potential for recurrence (as judged by the Site Investigator) with less than 4 weeks interval between
- •resolution of serious infection and first dose of study drug, or currently
- •active moderate to severe infection at Screening (Grade 2 or higher),
- •including active coronavirus disease 2019 (COVID-19)
- •- Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
- •- Active malignancy or history of malignancy within 5 years
- •- Conditions that may predispose the participant to excessive bleeding
- •- Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral corticosteroids
- •- Previous use of a BTK inhibitor.
- •- Has received any investigational drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
- •- Previous exposure to another investigative drug for CSU
- •- Positive for human immunodeficiency virus (HIV) antibody test.
- •- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit.
- •- Positive hepatitis C antibody test result at screening or within 3 months prior to the screening visit.
- •- Tuberculosis infection
- •- Any of significant laboratory abnormalities and ECG findings at the screening visit
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195